Seres increases authorized shares to 240M and updates on Oaktree credit facility tranche conditions

Seres Therapeutics, Inc.

Stockholders approved increase in authorized common shares from 200M to 240M; Certificate of Amendment filed June 27, 2023.
Company posted updated corporate presentation disclosing funding conditions for Tranche B and Tranche C of Oaktree Credit Facility.
Management states funding requirements for Tranche B and Tranche C are achievable.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.